Publication
Phase 1 Study of Anito-cel, a d-Domain BCMA CAR T Cell for Refractory or Recurrent Myeloma.
Matthew J Frigault, Binod Dhakal, Andrzej J Jakubowiak, Noopur Raje, Kamalika Banerjee, C Jenny Mu, Kevin C Hart, Sigal Shachar, Lawrence P Andrews, Laurene S Cheung, Faith M Griffin, Alexandra R Witter, Michael Hyde, Chester Pham, Nikitha Gandra, Tenzin Shakya, Bhargavi Rajan, Christa Cortesio, Samuel T Haile, Heba Nowyhed, Priyanka Nair-Gupta, Priyam Mitra, Rebecca J Chan, Ana Kostic, Christopher R Heery, Jacalyn Rosenblatt, Michael R Bishop
- Source
- PubMed
- Retrieved
- Sep 30, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260930-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
BACKGROUND: Anitocabtagene autoleucel (anito-cel), a B-cell maturation antigen (BCMA)-directed autologous chimeric antigen receptor (CAR) T-cell therapy with a synthetic d-domain binder (ddBCMA), may have efficacy in patients with relapsed or refractory multiple myeloma. METHODS: In a phase 1…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 1
- trialNCT04155749registry_reference1.00
Registered trialsNCT04155749
Curated evidence
Evidence citing this paper (0)
Data not yet available